Aveo Oncology of Cambridge and its Japanese partner Astellas Pharma said today the U.S. Food and Drug Administration has agreed to review its drug candidate for treating patients with advanced renal cell carcinoma.
The drug, called tivozanib, is an investigational medicine and is not currently approved in any country, the companies said. The FDA expects to complete its review by July 28.
If approved, the drug would be branded as Tivopath. The FDA's acceptance of the drug will also trigger a $15 million milestone payment to Aveo under its development and commercialization agreement with Astellas, which is based in Tokyo.
The companies said renal cell carcinoma accounts for more than 90 percent of all kidney cancers with more than 100,000 people dying from the disease each year.
Anda sedang membaca artikel tentang
FDA to review Aveo kidney cancer drug
Dengan url
http://emberemas.blogspot.com/2012/11/fda-to-review-aveo-kidney-cancer-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
FDA to review Aveo kidney cancer drug
namun jangan lupa untuk meletakkan link
FDA to review Aveo kidney cancer drug
sebagai sumbernya
0 komentar:
Posting Komentar